Back

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Interstitial/parenchymal lung disease

I.a

Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)
I.b

Pneumonitis (interstitial lung disease/ILD)
I.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.h

Subclinical pulmonary infiltrates/ILD
I.m

ILD with a granulomatous component

III - Pulmonary/alveolar/airway hemorrhage/bleeding

III.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

X - Systemic/Distant conditions, syndromes and reactions

X.d

Lupus - Lupus syndrome (see also Vd)
X.k

Sarcoid-like granulomatosis (endo-/extrathoracic)

XII - Cardiovascular involvement / toxicity

XII.d

Myocarditis (can be fulminant)
XII.k

Constrictive pericarditis - Pericardial thickening

XV - Pathology

XV.e

Path: ILD with a granulomatous component (see also Im)

XVII - Infections & related conditions

XVII.b

Opportunistic pulmonary/systemic infections
XVII.g

Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
XVII.h

Nontuberculous pulmonary mycobacterial infection/superinfection
XVII.n

Legionella pneumophila pneumonia

XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.c

BAL: An excess proportion of eosinophils